Novel therapies for Alzheimer’s disease, particularly anti-amyloid drugs like lecanemab and donanemab, have shown modest clinical benefits but also significant risks. The present paper highlights the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback